Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Long-Read Sequencing Reveals Cancer-Driving Changes Missed by Conventional Testing

By LabMedica International staff writers
Posted on 26 Oct 2026

Cancer diagnosis often relies on identifying genomic alterations that influence tumor behavior and treatment selection. More...

However, conventional short-read sequencing can miss complex DNA changes, leaving the underlying cause of genomic instability unresolved in some tumors. By reading longer stretches of the genome, long-read nanopore sequencing may help uncover these changes. New findings demonstrate this capability, revealing cancer-driving alterations that conventional methods failed to detect.

University of Michigan researchers incorporated long-read nanopore sequencing into Michigan’s Oncology Sequencing Program (MiOncoSeq), which launched in 2010 to analyze DNA and RNA from normal tissue and tumors for alterations that could guide treatment. The added technology reads thousands to tens of thousands of DNA letters in a single stretch, allowing researchers to examine complex changes and determine how they are arranged.

This capability can reveal whether one or both copies of a cancer-protective gene are disabled by complex DNA rearrangements or chemical modifications. It can also establish whether multiple mutations occur together on a single copy of a cancer-promoting gene, a configuration that may increase gene activity or contribute to drug resistance. 

In one arm of the study, researchers screened 768 patients with prostate, breast, or ovarian cancer and identified 46 tumors with genomic instability that conventional sequencing could not explain. Long-read sequencing resolved 32 of these cases by uncovering hidden alterations or chemical changes affecting cancer-protective genes.

In a broader analysis, the team screened 4,496 tumor samples from 3,688 MiOncoSeq patients, then used nanopore sequencing in selected cases to determine how mutations were arranged in genes including NOTCH1, PDGFRB, KIT, and PIK3CA. These findings were published in Cancer Discovery.

A separate study, published in the New England Journal of Medicine and involving University of Michigan collaborators, applied nanopore sequencing to a rare paraspinal tumor in a 3-year-old boy who had received gene therapy for Krabbe disease.

“Having a list of mutations doesn't always explain a tumor. We need to understand how these mutations are arranged, which conventional sequencing often cannot resolve,” said Arul Chinnaiyan, M.D., Ph.D., S.P. Hicks Professor of Pathology and Urology, director of the Michigan Center for Translational Pathology and a Howard Hughes Medical Institute investigator. 

“Gene therapy holds great promise, and understanding complications like this can help guide safer design. It is also important to monitor patients over the long term after they receive treatment,” added Dr. Chinnaiyan.

Related Links
University of Michigan 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.